2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-123272
    E6801 528859-04-3 98%
    E6801 is a 5-HT6 receptor agonist that improves recognition memory by jointly modulating cholinergic and glutamatergic neurotransmission. E6801 can be used in studies of dementia, depression, obesity, epilepsy, etc.
    E6801
  • HY-123280
    SCH 54388 25451-53-0 98%
    SCH 54388 is an orally active metabolite of Felbamate (HY-B0184). SCH 54388 markedly reduces the deficit-producing effects of Scopolamine (HY-N0296) or Dizocilpine (HY-15084B) in a dose-dependent manner without significant toxicity up to 300 mg/kg. SCH 54388 can be used for central neuronal systems related diseases research.
    SCH 54388
  • HY-123294
    Fentrazamide 158237-07-1 98%
    Fentrazamide (YRC 2388) is a herbicide. Fentrazamide has specific toxic effects on the nervous system and erythrocytes in rats, affecting the energy supply of cells mainly by interfering with the glycolysis process. Fentrazamide can be used as a useful tool to study the mechanisms of neurodegenerative diseases and erythrocyte dysfunction.
    Fentrazamide
  • HY-123332
    YM-08050 73328-60-6 98%
    YM-08050 is a new anti-psychotic and Benzamide (HY-Z0283) derivative. YM-08050 inhibits stereotyped behaviors, conditioned avoidance responses, or spontaneous movements induced by Apomorphine (HY-12723) or Methamphetamine.
    YM-08050
  • HY-123357
    IMM-H004 1456807-80-9 98%
    IMM-H004, a coumarin derivative, possesses neuroprotective and potent free radical scavenging abilities. IMM-H004 significantly inhibits amyloid-β (Aβ)-induced cytotoxicity and apoptosis, offering potential value for research into neurodegenerative diseases such as Alzheimer's disease. Additionally, IMM-H004 is also capable of effectively blocking the calcium mobilization and chemotaxis induced by CKLF1-C27 (HY-P3418), thereby alleviating asthmatic pathological changes in the lung tissue of CKLF1 transgenic mice.
    IMM-H004
  • HY-123376
    FR-190997 193344-25-1 98%
    FR-190997 is a non-peptide Bradykinin B2 receptor selective agonist, Ki value is 9.8 nM. FR-190997 is also an effective antihypertensive agent.
    FR-190997
  • HY-123382
    GSK-1482160 (isomer) 1695551-19-9 98%
    GSK-1482160 isomer is the isomer of GSK-1482160 (HY-19888). GSK-1482160 is an orally active and blood-brain barrier penetrant P2X7 receptor (P2X7R) negative allosteric modulator with pIC50s of 8.5 (human) and 6.5 (rat). GSK-1482160 reduces the efficacy of ATP at the P2X7 receptor without affecting its affinity, thereby inhibiting the release of IL-1β. GSK-1482160 is an effective radioligand and can be labeled with radioactive isotopes like 11C or 18F to image P2X7R. GSK-1482160 can be used for the studies of chronic joint pain and chronic constriction injury (CCI).
    GSK-1482160 (isomer)
  • HY-123395
    NSC-84096 908813-78-5 98%
    NSC-84096 is an endopeptidase activity inhibitor with the ability to inhibit the activity of botulinum neurotoxin type A light chain (rBoNT/A-LC). NSC-84096 is able to effectively inhibit the enzymatic activity of botulinum neurotoxin in vitro, indicating its potential in inhibiting botulism. The mechanism of action of NSC-84096 may provide hope for the development of small molecule compounds targeting these deadly toxins.
    NSC-84096
  • HY-123398
    RS-51324 69811-30-9 98%
    RS-51324 is an oral active antidepressant agent. RS-51324 inhibitts norepinephrine uptake and reverses of Reserpine (HY-N0480)-induced hypothermia.
    RS-51324
  • HY-123408
    Umespirone 107736-98-1 98%
    Umespirone (KC 9172) is a potential antipsychotic/antianxiety agent.
    Umespirone
  • HY-123411
    MGS0039 569686-87-9 98%
    MGS0039 is a type II group mGluR antagonist. MGS0039 has a high affinity for mGluR2 and mGluR3, with Ki values of 2.2 nM and 4.5 nM, respectively. MGS0039 can attenuate the inhibitory effect of glutamate-induced cyclic AMP formation triggered by Forskolin (HY-15371) in CHO cells expressing mGluR2/mGluR3. MGS0039 shows antidepressant-like activity in rats.
    MGS0039
  • HY-123414
    GX-936 1235406-09-3 98%
    GX-936 (PF-05196233), a potent and Nav1.7-subtype selective inhibitor, binds to the activated state of voltage-sensor domain IV (VSD4).
    GX-936
  • HY-123433
    JNJ-40068782 950196-50-6 98%
    JNJ-40068782 is a potent positive allosteric modulator of the mGlu2 receptor, with the IC50 of 38 nM.
    JNJ-40068782
  • HY-123439
    FTY720-C2 249289-10-9 98%
    FTY720-C2 is a derivative of FTY72 (HY-12005). FTY720-C2 promotes the expression of brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF) in multiple system atrophy (MSA) models, without causing immunosuppression. FTY720-C2 improves motor dysfunction and reduces the levels of insoluble alpha-synuclein (αSyn) in MSA mouse models. FTY720-C2 is blood-brain barrier penetrate.
    FTY720-C2
  • HY-123442
    L 775,606 188400-51-3 98%
    L 775,606 is a potent and selective 5-HT1D receptor agonist. L 775,606 can be used to study migraine headache.
    L 775,606
  • HY-123446
    JNJ-42259152 1301167-87-2 98%
    JNJ-42259152 is a phosphodiesterase 10A (PDE10A) positron emission tomography (PET) tracer that is specific for PDE10A activity. JNJ-42259152 can be dynamically scanned in healthy volunteers to assess its kinetic properties in the brain. The half-life of JNJ-42259152 in the blood is an average of 90 minutes. JNJ-42259152 has demonstrated reliable binding potential (BPND) in different target areas (such as the lentiform nucleus, caudate nucleus, ventral striatum, etc.), providing an important tool for studying neuropsychiatric diseases.
    JNJ-42259152
  • HY-123469
    RS-0466 536993-37-0 98%
    RS-0466, a neuroprotective compound, inhibits β-amyloid-induced cytotoxicity. RS-0466 can be used for research of Alzheimer’s disease.
    RS-0466
  • HY-123473
    SB-414796 264262-71-7 98%
    SB-414796 is a selective, orally active and cross the blood-brain barrier dopamine D3 receptor antagonist with Ki values of 4, 400 nM for D3, D2, respectively.
    SB-414796
  • HY-123478
    Fengabine 80018-06-0 98%
    Fengabine is a GABAergic antidepressant agent. Fengabine can be used for the research of depression.
    Fengabine
  • HY-123480
    EGIS-7625 755040-97-2 98%
    EGIS-7625 is a selective and competitive 5-HT2B inhibitor with pKi values of 9.0, 6.2, 7.7 for 5-HT2B, 5-HT2A, 5-HT2C, respective. EGIS-7625 partially attenuates m-chlorophenylpiperazine-induced hypomotility and hypophagia.
    EGIS-7625
Cat. No. Product Name / Synonyms Application Reactivity